BCRP Inhibitors: Mechanisms, Types, and Clinical Implications

BCRP inhibitors are compounds that block the activity of breast cancer resistance protein, a molecular pump found on cell surfaces throughout the body that ejects drugs and other molecules before they can take effect. By shutting down this pump, BCRP inhibitors can boost the absorption of certain medications, help chemotherapy drugs reach tumors that have learned to resist them, and improve the delivery of treatments into hard-to-reach tissues like the brain. But the same mechanism that makes these inhibitors therapeutically interesting also makes them a source of dangerous drug-drug interactions, where one medication inadvertently disables the pump and causes a second medication to accumulate to toxic levels.

What BCRP Actually Does in the Body

BCRP, formally known as ABCG2, is a protein embedded in cell membranes that uses energy from ATP to push a wide range of molecules out of cells. It belongs to a family of transporters called ABC (ATP-binding cassette) proteins, which collectively act as gatekeepers controlling what gets into and out of different tissues. BCRP sits on the outward-facing surface of cells lining the intestine, liver, kidney, placenta, blood-brain barrier, and blood-testis barrier, among other locations.¹ In each of these spots, it performs a slightly different job, but the basic function is the same: it intercepts molecules and shoves them back where they came from.

In the intestinal lining, BCRP limits how much of an orally taken drug actually makes it into the bloodstream by pumping a portion of it back into the gut. In the liver and kidneys, it helps clear waste products and drug metabolites into bile and urine. At the blood-brain barrier, it keeps many drugs out of the central nervous system entirely. And in the placenta, it protects the developing fetus from potentially harmful substances circulating in the mother’s blood.² BCRP also transports endogenous substances like estrogen metabolites, porphyrins (precursors to heme), and uric acid, making it relevant to conditions well beyond cancer treatment.

How BCRP Inhibitors Work

The basic mechanism is straightforward in concept: a BCRP inhibitor binds to the transporter protein and prevents it from pumping substrates out of the cell. Structural studies using cryo-electron microscopy have revealed that potent inhibitors wedge themselves into the central, inward-facing cavity of the BCRP protein, physically blocking the space where drug molecules would normally bind and preventing the shape change the protein needs to undergo to push those molecules out.³ The transporter essentially gets stuck in an inactive conformation. Without the ability to cycle through its pumping motion, it sits idle while drug molecules accumulate inside the cell or pass through tissue barriers unimpeded.

This mechanism has two broad consequences depending on where BCRP is being inhibited. In the gut, blocking BCRP allows more of an oral drug to be absorbed into the bloodstream, raising its plasma concentration. At a tumor cell surface, blocking BCRP traps chemotherapy drugs inside cancer cells that would otherwise expel them. These are the two scenarios that drive most of the clinical interest in BCRP inhibition.

Types of BCRP Inhibitors

BCRP inhibitors fall into a few broad categories based on their origin and intended use. Understanding these categories matters because the clinical context for each is very different.

Research-Grade Synthetic Inhibitors

The best-known BCRP inhibitor in laboratory settings is fumitremorgin C (FTC), a fungal toxin that selectively and potently blocks BCRP at micromolar concentrations.⁴ FTC became the reference compound for BCRP research because it was one of the first molecules found to specifically target this transporter without significantly affecting the related pump P-glycoprotein. However, FTC is neurotoxic, which rules it out for human use.

To get around this problem, researchers developed Ko143, a synthetic derivative of FTC that retains high potency against BCRP but is less toxic. Ko143 became the gold-standard tool compound for in vitro BCRP research and is widely used in laboratory assays. Its limitation is that it breaks down rapidly in the body, getting hydrolyzed to an inactive form before it can do much work in a living organism.⁵ Efforts to redesign Ko143 into something metabolically stable enough for clinical use are ongoing, but no direct descendant has reached patients yet.

Flavonoids and Dietary Compounds

A surprisingly large number of natural compounds found in food inhibit BCRP. Flavonoids, a class of plant-derived molecules present in fruits, vegetables, tea, and wine, are especially active. Among the flavonoid subclasses, flavones and flavonols appear to be the strongest inhibitors.⁶ Some specific flavones isolated from traditional medicinal plants, such as retusin and ayanin, approach the potency of Ko143 in laboratory tests.⁷

The practical significance here is not that eating an orange will disable your BCRP. Dietary flavonoid intake from normal meals is generally too low and too transient to cause a meaningful drug interaction. But concentrated supplements, grapefruit juice consumed in large quantities, and herbal preparations can create conditions where intestinal BCRP is temporarily impaired. If you happen to be taking a drug that depends on BCRP to regulate its absorption, that impairment could push blood levels of the drug higher than expected. This is the same basic dynamic as the well-known grapefruit-drug interaction with liver enzymes, just involving a different molecular target.

Marketed Drugs That Incidentally Inhibit BCRP

Many medications already on the market turn out to inhibit BCRP as an unintended side activity. This is actually the most clinically relevant category, because these drugs are being prescribed to real patients who may also be taking BCRP substrates. Regulatory agencies now require that new drug candidates be tested for BCRP inhibition. According to both the FDA and the European Medicines Agency, if a new drug’s expected concentration in the intestinal lumen exceeds its BCRP-inhibiting concentration by tenfold or more, a clinical drug interaction study is warranted.⁸

The Rosuvastatin Problem

The clearest real-world illustration of BCRP inhibition causing trouble involves rosuvastatin, a widely prescribed cholesterol-lowering statin. Rosuvastatin is a well-established BCRP substrate, and its absorption from the gut is heavily regulated by the transporter.⁹ When BCRP function is reduced, more rosuvastatin gets through the intestinal wall and into the bloodstream.

A clinical study with fostamatinib, a drug used for chronic immune thrombocytopenia that also inhibits BCRP, demonstrated this effect clearly. Co-administration roughly doubled rosuvastatin’s plasma exposure, which is a large enough increase to raise the risk of statin side effects including muscle damage.¹⁰ The finding confirmed that blocking BCRP alone, without involving other transporters, is enough to create a clinically meaningful change in drug levels.

An even more alarming example involves ticagrelor, an antiplatelet drug commonly prescribed alongside statins after heart attacks. A case series documented rhabdomyolysis, a serious condition where muscle tissue breaks down and can damage the kidneys, in patients taking both ticagrelor and rosuvastatin. A broader look through adverse-event databases turned up more than 40 such reports, including three deaths. Laboratory testing showed that ticagrelor inhibits BCRP-mediated transport of rosuvastatin and is predicted to roughly double rosuvastatin plasma levels through intestinal BCRP blockade.¹¹ Since both drugs are frequently co-prescribed in cardiac patients, this interaction deserves more attention than it currently gets.

Overcoming Cancer Drug Resistance

BCRP was originally identified in cancer cells that had become resistant to chemotherapy, and reversing that resistance remains the primary therapeutic ambition for BCRP inhibitors. The protein was first characterized in a breast cancer cell line, hence the name, but its role in drug resistance extends across many tumor types.

Certain chemotherapy drugs are especially affected. Topoisomerase I inhibitors like topotecan, irinotecan’s active metabolite SN-38, and the related compound 9-aminocamptothecin face pronounced resistance when BCRP is overexpressed, as does mitoxantrone.¹² In non-small cell lung cancer cells, BCRP levels explained roughly 80 to 90 percent of the variation in resistance to topoisomerase I inhibitors, and the tyrosine kinase inhibitor gefitinib could partially reverse that resistance by blocking BCRP and increasing intracellular drug accumulation in proportion to BCRP expression.¹³

In many real tumors, BCRP is not the only efflux pump causing problems. P-glycoprotein, another ABC transporter, often works alongside BCRP to expel overlapping sets of drugs. This has driven interest in dual inhibitors that block both BCRP and P-glycoprotein simultaneously, since knocking out only one pump may simply shift the drug-resistance burden to the other.¹⁴ Several dual-targeting compounds have been described in recent years, though none have advanced far in clinical trials. The challenge is always the same: potent enough to restore drug sensitivity in the tumor, selective enough not to wreck normal tissue protection elsewhere in the body.

Getting Drugs Into the Brain

The blood-brain barrier is one of the body’s tightest defenses, and BCRP is one of its key enforcers. Sitting on the surface of endothelial cells that line the brain’s tiny blood vessels, BCRP pumps many drugs back into the bloodstream before they can enter the brain tissue. This is a major obstacle for treating brain tumors and neurological diseases.¹⁵

Inhibiting BCRP at the blood-brain barrier is a logical strategy to improve brain penetration of cancer drugs, particularly for patients with brain metastases or primary brain tumors. Both BCRP and P-glycoprotein are present at this barrier, and animal studies in knockout mice show that removing both pumps dramatically increases brain concentrations of many drugs.¹⁶ The difficulty, again, is doing this safely. The blood-brain barrier exists for a reason. Disabling it pharmacologically risks letting in not just the intended drug but also toxins, metabolites, and other circulating molecules that the brain is normally shielded from. Any clinical strategy would need to be highly targeted, ideally timed around chemotherapy dosing and cleared quickly enough to let the barrier recover.

When Genetics Mimics Inhibition

Some people walk around with naturally reduced BCRP function due to inherited genetic variants. The most studied is a single-letter change in the ABCG2 gene known as c.421C>A, which produces a version of the protein (Q141K) that doesn’t reach the cell surface as efficiently. People carrying this variant have lower BCRP activity, which translates into higher blood levels of BCRP substrate drugs after a standard dose. Detailed pharmacokinetic studies have confirmed that the difference comes mainly from increased intestinal absorption rather than changes in how drugs are cleared by the liver or kidneys.¹⁷

This variant is remarkably common, carried by roughly 30 percent of people of East Asian descent and around 10 to 15 percent of people of European descent. Its effects extend beyond drug handling. Because BCRP is a major transporter of uric acid, reduced BCRP function leads to higher circulating uric acid levels and an increased risk of gout. A study of Japanese individuals found that those with severely reduced BCRP function (carrying two copies of this or other loss-of-function variants) had dramatically elevated gout risk, with odds ratios reaching as high as about 26 compared to people with fully functional BCRP.¹⁸

People with the Q141K variant are essentially experiencing a permanent, low-level version of what a BCRP inhibitor drug does temporarily. This makes them a natural experiment for understanding what happens when BCRP is blocked. It also means they are at higher baseline risk from any additional BCRP inhibition by drugs. A patient who already absorbs more rosuvastatin than average because of their genetics, and then starts taking a BCRP-inhibiting medication on top of that, could face a compounded increase in statin exposure.

Species Differences in BCRP Research

One underappreciated wrinkle in BCRP research is that the human version and the mouse version of the protein do not respond identically to inhibitors. Much of what we know about BCRP comes from studies in mice, including knockout animals that lack the transporter entirely. But when researchers compared the potency of fumitremorgin C against human BCRP versus mouse Bcrp1, they found that the human transporter was significantly more sensitive to inhibition, requiring lower concentrations to block transport of substrates like mitoxantrone and nitrofurantoin.¹⁹

This difference matters for drug development. If a candidate BCRP inhibitor looks only moderately effective in mouse studies, it could be substantially more potent in humans. Conversely, toxicity concerns identified in mice might underestimate or misrepresent the actual risk in patients. Researchers developing BCRP inhibitors for clinical use increasingly rely on cell lines expressing the human transporter and validated human membrane-based assay systems rather than assuming mouse data will translate directly.

How BCRP Inhibition Is Tested in Drug Development

Before a new drug reaches patients, regulatory agencies expect its interactions with BCRP to be characterized. The standard laboratory approach uses membrane vesicle assays, where tiny bubbles of cell membrane containing BCRP are incubated with known substrates and the test compound. If the test compound reduces the transport of substrates like estrone-3-sulfate, methotrexate, or rosuvastatin into the vesicles, it is flagged as a BCRP inhibitor. Reference inhibitors like sulfasalazine, novobiocin, and fumitremorgin C serve as positive controls, with sulfasalazine typically showing a half-maximal inhibitory concentration in the sub-micromolar range.²⁰

The regulatory decision tree then compares the drug’s expected intestinal concentration to its in vitro inhibitory potency. If the ratio exceeds the threshold set by agencies like the FDA and EMA, a clinical drug interaction study with a sensitive BCRP substrate (typically rosuvastatin or sulfasalazine) is required before the drug can be approved.⁸ This is why many drug labels now contain specific language about BCRP interactions and dose adjustment recommendations when co-prescribed with known substrates. The system is not perfect — it relies on somewhat conservative predictions — but it catches the most obvious risks before drugs reach widespread use.

Why No BCRP Inhibitor Has Become a Standalone Drug

Given how much research has gone into BCRP inhibitors over the past two decades, the absence of an approved drug specifically designed to block BCRP is striking. The reasons are mostly practical rather than scientific. First, selectivity is a persistent problem. Many potent BCRP inhibitors also hit other transporters or enzymes, making it hard to attribute clinical effects to BCRP blockade alone and raising the risk of unpredictable side effects. Second, the most selective research tools like FTC and Ko143 have pharmacological liabilities that prevent them from being used in people: neurotoxicity for FTC, rapid metabolism for Ko143.⁵

Third, and perhaps most fundamentally, BCRP does too many useful things. A drug that blocked BCRP systemically would impair the blood-brain barrier, the placental barrier, uric acid excretion, porphyrin clearance, and drug elimination through the liver and kidneys all at once. The therapeutic window between useful inhibition at a tumor site and harmful inhibition everywhere else is narrow. Strategies to address this include designing inhibitors that work only in the gut (to boost oral drug absorption without affecting other tissues), timing inhibitor doses to coincide narrowly with chemotherapy infusions, and developing tumor-targeted delivery systems. None of these have matured to the point of clinical approval, but the ongoing work to design stable, selective, non-toxic BCRP inhibitors with derivatives of Ko143 and other scaffolds reflects the field’s conviction that the target is worth pursuing.²¹